NICOX chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.18
Dividend & YieldN/A€ (N/A)
Beta 0.96
Market capitalization 40.18M
Operating cash flow -18.57M
ESG Scores unknown

Company description

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio5.97
Working Capital-1.1
Return On Equity-0.58
Debt To Equity0.28
Fixed Asset Ratio0.37
Fixed Interest Cover-3.76

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 51k -636k 2.41M -2.1M
Total Cashflows From Investing Activities -270k -95k 4.95M -175k
Net Borrowings 10.89M 10.89M 6.26M -395k
Total Cash From Financing Activities 22.18M 22.18M 19.58M 13.41M
Change To Operating Activities -299k 383k 128k -716k
Issuance Of Stock 11.29M 11.29M 13.95M 13.8M
Net Income -18.39M -18.92M -18.1M -43.76M
Change In Cash -19.34M 6.04M 19.09M -5.22M
Effect Of Exchange Rate 78k 6k -48k 21k
Total Cash From Operating Activities -19.14M -16.05M -5.39M -18.48M
Depreciation 150k 981k 1.74M 1.66M
Change To Account Receivables -838k -8k -1.8M 274k
Other Cashflows From Financing Activities
Change To Netincome 184k 1.98M 9.59M 26.17M
Capital Expenditures -228k -63k -20k -8k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 17.91M 17.91M 17.91M 17.91M
Income Before Tax -18.28M -22.78M -18.07M -47.41M
Net Income -18.39M -18.92M -18.1M -43.76M
Selling General Administrative 9.51M 7.67M 6.68M 7M
Gross Profit -12.3M -10.89M 179k 7.23M
Ebit -21.24M -18.26M -6.9M -18.25M
Operating Income -21.24M -18.26M -6.9M -18.25M
Interest Expense 1.55M 865k -2.21M -4.85M
Income Tax Expense 113k -3.86M 28k -3.64M
Total Revenue 4.03M 6.86M 12.91M 7.23M
Cost Of Revenue 16.33M 17.75M 12.73M 17.91M
Total Other Income ExpenseNet 2.96M -4.52M -11.17M -29.16M
Net Income From Continuing Ops -18.39M -18.92M -18.1M -43.76M
Net Income Applicable To Common Shares -18.39M -18.92M -18.1M -43.76M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 24.94M 33.51M 41.43M 39.06M
Total Stockholder Equity 113.65M 109.3M 100.83M 75.55M
Other Current Liabilities 2.02M 810k 5.52M 4M
Total Assets 138.59M 142.81M 142.27M 114.61M
Common Stock 29.72M 33.23M 37.03M 43.14M
Other Current Assets 377k
Retained Earnings -18.39M -18.92M -18.1M -508.89M
Treasury Stock -408.36M -423.45M -446.69M 5.11M
Cash 22.06M 28.1M 47.2M 41.97M
Total Current Liabilities 8.07M 9.83M 15.4M 8M
Other Stockholder Equity -408.36M -423.45M -446.09M 5.95M
Property, Plant, and Equipment 269k 1.67M 1.17M 1.02M
Total Current Assets 26.09M 32.15M 52.52M 47.74M
Net Tangible Assets 16.9M 11.33M 12.32M 9.94M
Net Receivables 2.55M 3.23M 2.7M 2.54M
Accounts Payable 4.28M 5M 2.42M 3.65M


Insider Transactions

Here are the insider transactions of stock shares related to NICOX:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to NICOX. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on NICOX

Here is the result of two systematic investment strategies applied to NICOX. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on NICOX

The following chart shows the equity curve of the two systematic investment strategies applied to NICOX:

NICOX automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -27.22% on the backtest period.

Performance at glance

Performance

-27.22 %

Latent gain

-476.7 €

Invested capital

1751.07 €

Annualized return

-6.67 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on NICOX

This is the result of two momentum investment strategies applied to NICOX. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on NICOX

The following chart shows all the entries opened by the momentum investment system on NICOX:

NICOX momentum entries
  • The first momentum investment strategy would give -31.12% of return on NICOX. That represents -1245.79€ of latent gain with 4003.18€ of employed capital.
  • The second momentum investment strategy would give -23.65% of return on NICOX. That represents -828.2€ of latent gain with 3502.13€ of employed capital.
Performance at glance (1Q Momentum)

Performance

-31.12 %

Latent gain

-1245.79 €

Invested capital

4003.18 €

Annualized return

-7.75 %
Performance at glance (2Q Momentum)

Performance

-23.65 %

Latent gain

-828.2 €

Invested capital

3502.13 €

Annualized return

-6.57 %

Momentum equity curve on NICOX

The following chart shows the equity curve of the two momentum strategies applied to NICOX:

NICOX momentum equity

Note: the dividends potentially given by NICOX are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on NICOX

The following chart shows the employed capital evolution of the two momentum strategies on NICOX since the beginning:

NICOX

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250€, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000€.


Buy the dip strategy result on NICOX

Buy the dip entry openings on NICOX

NICOX

The performance achieved by the robo-advisor on NICOX is -16.12%. That represents -282.43$ of latent gain with 1752.61€ of employed capital. The following chart shows NICOX stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of NICOX, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-16.12 %

Latent gain

-282.43 €

Invested capital

1752.61 €

Annualized return

-7.75 %

Equity curve of the strategy applied to NICOX

The following chart shows the result of the investment strategy applied to NICOX:

NICOX

Note: the dividends potentially given by NICOX are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on NICOX

The following chart shows the employed capital evolution since the beginning of the investment strategy on NICOX:

NICOX

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on NICOX

In this section, I will compare the three previous investment strategies applied to NICOX.

Equity curve comparison on NICOX

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

NICOX investment strategy comparison

Employed capital comparison on NICOX

NICOX investment comparison

Performance comparison on NICOX

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -27.22% -476.7€ 1751.07€ -6.67%
Momentum 1 quarter -31.12% -1245.79€ 4003.18€ -8.1%
Momentum 2 quarters -23.65% -828.2€ 3502.13€ -6.57%
Non-directional -16.12% -282.43€ 1752.61€ -7.75%
Annualized return comparison

Automatic investment

-6.67 %

Momentum 1Q

-6.57 %

Momentum 2Q

-6.57 %

Non-directional

-7.75 %

Correlated stocks

Here are the most positively and negatively correlated stocks with NICOX:

Positive correlations

Most correlated stocks this year

  • NICOX

  • Most correlated stocks last 3 months

  • NICOX
  • XD INC

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • LOGAN PPT
  • WKK INTL (HOLD)
  • Concord Medical Services

  • Note: The algorithm computes the probability of correlation between NICOX and the other stocks. There may be false positives or some missing correlated stocks. If the price of NICOX does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name NICOX
    Country France
    City Valbonne
    Address 2405 Route Des Dolines Drakkar D
    Phone 33 4 97 24 53 00
    Website www.nicox.com
    FullTime employees 32
    Industry Biotechnology
    Sector Healthcare
    Exchange XPAR
    Ticker COX.XPAR
    Market www.euronext.com

    NICOX ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown